Cellestive™ leverages the success of immune rodents in raising diverse and developable Abs. It can interrogate and isolate different B-cell populations using the same well-established technology (i.e., FACS), further enabling the diversity of Abs obtained.
CellestiveTM — the consultative discovery platform developed by Antibody Solutions — empowers clients to choose the best possible discovery pathways for their discovery program based upon their target, timeline, budget, and, most importantly, the vision they have for their novel antibody drug.
We invite you to download our poster that details this research study, including our antibody discovery strategy as well as the Spike protein reagents, screening assay formats, and more that we utilized.
Joshua Lowitz, Glen Lin, Avery Van Horn, Jennifer Somera, Ryan Kim, Rick Chang, Catherine Vo, Ronald Gamatero, Opal Arenas, Emmeline Truong, Nicholas Wameling, Birthe Jessen^, Heather Schwoebel, Mike Snaith, and John S. Kenney, Antibody Solutions, Sunnyvale, Calif., USA & Alloy Therapeutics, Hanover, N.H., USA